Related Experiment Video
Updated: Jan 13, 2026
07:30
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
3.4K
Homocysteine levels do not impact cognitive profile in frontotemporal dementia
Oscar Prata1, Veronica Cherubini1, Valentina Ranaldi2
1Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Via Conca 1, Ancona, Italy.
Summary
High homocysteine (Hcy) levels do not appear to impact cognitive functions in individuals with Frontotemporal Dementia (FTD). This study found no significant association between elevated Hcy and cognitive performance in FTD patients.
Area of Science:
- Neuroscience
- Neurology
- Cognitive Science
Background:
- Homocysteine (Hcy) is a known risk factor for cerebrovascular disorders and Alzheimer's Disease.
- The specific role of Hcy in other neurodegenerative dementias, like Frontotemporal Dementia (FTD), is not well understood.
- It remains unclear if elevated Hcy causes general cognitive decline or selectively impairs specific cognitive domains in FTD.
Purpose of the Study:
- To investigate the association between high plasma homocysteine (Hcy) levels and specific cognitive functions in individuals diagnosed with Frontotemporal Dementia (FTD).
- To determine if Hcy influences global cognitive decline or specific cognitive domains in FTD.
- To clarify the potential role of Hcy as a risk factor in FTD, moving beyond global cognitive assessments.
Main Methods:
- A cross-sectional study involving 173 patients diagnosed with FTD.
- Comprehensive neuropsychological evaluation across multiple cognitive domains: memory, language, visuoperception, visuospatial abilities, executive functioning, constructional praxis, and ideomotor praxis.
- Analysis of plasma Hcy levels alongside other risk factors including cholesterol, smoking, triglycerides, and APOE ε4 allele presence.
Main Results:
- A Generalized Linear Model analysis was employed to assess the relationship between Hcy levels and cognitive performance.
- No statistically significant association was found between elevated plasma homocysteine (Hcy) levels and cognitive performance across any assessed domain in the FTD cohort.
Conclusions:
- Plasma Hcy levels were not significantly associated with cognitive performance in a substantial sample of individuals with Frontotemporal Dementia (FTD).
- These findings suggest that Hcy may not be a significant risk factor for cognitive impairment in FTD.
- Further research replicating these results could challenge the existing hypothesis regarding Hcy's role in FTD pathogenesis.
Keywords:
Alzheimer’s diseaseCognitive profileFrontotemporal dementiaHomocysteineHyperhomocysteinemiaNeuropsychologyMore Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
529
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
529
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:23Role of Neurotransmitters in Memory
2.5K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.5K
01:30Negative and Cognitive Symptoms of Schizophrenia
434
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
434
01:29Therapeutic Drug Monitoring: Affecting Factors
193
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
193
01:30Dementia
508
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
508